Your browser doesn't support javascript.
Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant.
Gao, Yu; Cai, Curtis; Grifoni, Alba; Müller, Thomas R; Niessl, Julia; Olofsson, Anna; Humbert, Marion; Hansson, Lotta; Österborg, Anders; Bergman, Peter; Chen, Puran; Olsson, Annika; Sandberg, Johan K; Weiskopf, Daniela; Price, David A; Ljunggren, Hans-Gustaf; Karlsson, Annika C; Sette, Alessandro; Aleman, Soo; Buggert, Marcus.
  • Gao Y; Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Cai C; Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Grifoni A; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA, USA.
  • Müller TR; Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Niessl J; Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Olofsson A; Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Humbert M; Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Hansson L; Department of Hematology, Karolinska University Hospital, Stockholm, Sweden.
  • Österborg A; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
  • Bergman P; Department of Hematology, Karolinska University Hospital, Stockholm, Sweden.
  • Chen P; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
  • Olsson A; Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Sandberg JK; Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
  • Weiskopf D; Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Price DA; Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
  • Ljunggren HG; Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Karlsson AC; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA, USA.
  • Sette A; Division of Infection and Immunity, Cardiff University School of Medicine, University Hospital of Wales, Cardiff, UK.
  • Aleman S; Systems Immunity Research Institute, Cardiff University School of Medicine, University Hospital of Wales, Cardiff, UK.
  • Buggert M; Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Stockholm, Sweden.
Nat Med ; 28(3): 472-476, 2022 03.
Article in English | MEDLINE | ID: covidwho-1632511
ABSTRACT
The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron (B.1.1.529) variant of concern (VOC) has destabilized global efforts to control the impact of coronavirus disease 2019 (COVID-19). Recent data have suggested that B.1.1.529 can readily infect people with naturally acquired or vaccine-induced immunity, facilitated in some cases by viral escape from antibodies that neutralize ancestral SARS-CoV-2. However, severe disease appears to be relatively uncommon in such individuals, highlighting a potential role for other components of the adaptive immune system. We report here that SARS-CoV-2 spike-specific CD4+ and CD8+ T cells induced by prior infection or BNT162b2 vaccination provide extensive immune coverage against B.1.1.529. The median relative frequencies of SARS-CoV-2 spike-specific CD4+ T cells that cross-recognized B.1.1.529 in previously infected or BNT162b2-vaccinated individuals were 84% and 91%, respectively, and the corresponding median relative frequencies for SARS-CoV-2 spike-specific CD8+ T cells were 70% and 92%, respectively. Pairwise comparisons across groups further revealed that SARS-CoV-2 spike-reactive CD4+ and CD8+ T cells were functionally and phenotypically similar in response to the ancestral strain or B.1.1.529. Collectively, our data indicate that established SARS-CoV-2 spike-specific CD4+ and CD8+ T cell responses, especially after BNT162b2 vaccination, remain largely intact against B.1.1.529.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: CD4-Positive T-Lymphocytes / CD8-Positive T-Lymphocytes / Cross Protection / SARS-CoV-2 / COVID-19 Type of study: Experimental Studies / Observational study / Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: Nat Med Journal subject: Molecular Biology / Medicine Year: 2022 Document Type: Article Affiliation country: S41591-022-01700-x

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: CD4-Positive T-Lymphocytes / CD8-Positive T-Lymphocytes / Cross Protection / SARS-CoV-2 / COVID-19 Type of study: Experimental Studies / Observational study / Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: Nat Med Journal subject: Molecular Biology / Medicine Year: 2022 Document Type: Article Affiliation country: S41591-022-01700-x